Ten63 Therapeutics Closes AI Drug Discovery Round

- Ten63's BEYOND platform, its core technology, is described as the first Large Quantum Chemistry Model (LQCM), designed to simulate trillions of potential drug molecules with a high degree of accuracy. The company's name itself, "Ten63," signifies the estimated 10^63 power of compounds that possess therapeutic properties. - A significant focus for the company is targeting "undruggable" proteins, which are estimated to constitute about 80% of all human proteins. A primary target is the oncogene Myc, implicated in up to 70% of all cancers and has been notoriously difficult to inhibit with drugs. - The company originated from over 15 years of academic research at Duke University. Co-founders include Marcel Frenkel (CEO), Mark Hallen (CTO), and Bruce Donald, a professor at Duke. The initial idea was sparked by CEO Marcel Frenkel's personal experience with his mother's illness. - Beyond its internal oncology pipeline, Ten63 Therapeutics has entered into strategic partnerships, including a multi-target drug discovery collaboration with Boehringer Ingelheim. It also received a grant from the Gates Foundation to develop affordable treatments for HPV-related cancers. - For consumer health apps, HIPAA compliance is a major consideration, but it generally applies only when the app is provided by or on behalf of a "covered entity" like a healthcare provider or insurer. Most direct-to-consumer wellness and symptom tracking apps fall outside of HIPAA's scope, and are instead governed by the FTC's Health Breach Notification Rule. - AI-powered symptom checkers are a growing area in consumer health, but their accuracy remains a challenge. Studies have shown that the correct diagnosis appears in the top five suggestions only about half the time. However, AI-driven mental health apps have shown more consistent positive outcomes, with some studies indicating a 22% to 43% reduction in depressive symptoms. - Successful user acquisition for health apps often involves a multi-pronged approach, including content marketing, collaborations with influencers, and offering free trials. Retaining users is equally critical and can be improved through reward programs, creating a sense of community, and a seamless onboarding experience. - For founders transitioning from a technical role to CEO in the digital health space, a common piece of advice is to engage with "proxy customers" (like clinicians) early on to validate ideas and to plan for integration with Electronic Health Records (EHRs) from the beginning. Many successful digital health founders are driven by a personal connection to the problem they are solving.